348 related articles for article (PubMed ID: 24553179)
1. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.
Rumi E; Harutyunyan AS; Pietra D; Milosevic JD; Casetti IC; Bellini M; Them NC; Cavalloni C; Ferretti VV; Milanesi C; Berg T; Sant'Antonio E; Boveri E; Pascutto C; Astori C; Kralovics R; Cazzola M;
Blood; 2014 Apr; 123(15):2416-9. PubMed ID: 24553179
[TBL] [Abstract][Full Text] [Related]
2. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
3. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Rumi E; Pietra D; Ferretti V; Klampfl T; Harutyunyan AS; Milosevic JD; Them NC; Berg T; Elena C; Casetti IC; Milanesi C; Sant'antonio E; Bellini M; Fugazza E; Renna MC; Boveri E; Astori C; Pascutto C; Kralovics R; Cazzola M;
Blood; 2014 Mar; 123(10):1544-51. PubMed ID: 24366362
[TBL] [Abstract][Full Text] [Related]
4. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ
J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950
[TBL] [Abstract][Full Text] [Related]
5. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
[TBL] [Abstract][Full Text] [Related]
6. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
7. Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.
Park SH; Kim SY; Lee SM; Yi J; Kim IS; Kim HH; Chang CL; Lee EY; Song MK; Shin HJ; Chung JS
Ann Lab Med; 2015 Mar; 35(2):233-7. PubMed ID: 25729726
[TBL] [Abstract][Full Text] [Related]
8. Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations.
Li N; Yao QM; Gale RP; Li JL; Li LD; Zhao XS; Jiang H; Jiang Q; Jiang B; Shi HX; Chen SS; Liu KY; Huang XJ; Ruan GR
Leuk Res; 2015 May; 39(5):510-4. PubMed ID: 25746303
[TBL] [Abstract][Full Text] [Related]
9. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
Nangalia J; Massie CE; Baxter EJ; Nice FL; Gundem G; Wedge DC; Avezov E; Li J; Kollmann K; Kent DG; Aziz A; Godfrey AL; Hinton J; Martincorena I; Van Loo P; Jones AV; Guglielmelli P; Tarpey P; Harding HP; Fitzpatrick JD; Goudie CT; Ortmann CA; Loughran SJ; Raine K; Jones DR; Butler AP; Teague JW; O'Meara S; McLaren S; Bianchi M; Silber Y; Dimitropoulou D; Bloxham D; Mudie L; Maddison M; Robinson B; Keohane C; Maclean C; Hill K; Orchard K; Tauro S; Du MQ; Greaves M; Bowen D; Huntly BJP; Harrison CN; Cross NCP; Ron D; Vannucchi AM; Papaemmanuil E; Campbell PJ; Green AR
N Engl J Med; 2013 Dec; 369(25):2391-2405. PubMed ID: 24325359
[TBL] [Abstract][Full Text] [Related]
10. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
11. [Clinical and biological features of patients with essential thrombocythaemia according to their mutational status JAK2 or CALR: Single-center study of 40 patients and review of the literature].
Ben Said M; Gandrille S; Fischer AM; Darnige L
Pathol Biol (Paris); 2015 Jun; 63(3):117-21. PubMed ID: 25840625
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
Kang MG; Choi HW; Lee JH; Choi YJ; Choi HJ; Shin JH; Suh SP; Szardenings M; Kim HR; Shin MG
Oncotarget; 2016 Aug; 7(35):57036-57049. PubMed ID: 27486987
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
[TBL] [Abstract][Full Text] [Related]
14. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.
Misawa K; Yasuda H; Araki M; Ochiai T; Morishita S; Shirane S; Edahiro Y; Gotoh A; Ohsaka A; Komatsu N
Int J Hematol; 2018 Jun; 107(6):673-680. PubMed ID: 29464483
[TBL] [Abstract][Full Text] [Related]
15. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
[TBL] [Abstract][Full Text] [Related]
16. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.
Poluben LO; Neumerzhytska LV; Klymenko SV; Fraenkel P; Balk C; Shumeiko OO
Probl Radiac Med Radiobiol; 2020 Dec; 25():362-373. PubMed ID: 33361847
[TBL] [Abstract][Full Text] [Related]
17. Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center.
Palova M; Szotkowski T; Hlusi A; Indrak K; Navratilova J; Divoka M; Papajik T
Neoplasma; 2018; 65(2):296-303. PubMed ID: 29534592
[TBL] [Abstract][Full Text] [Related]
18. Presence of calreticulin mutations in JAK2-negative polycythemia vera.
Broséus J; Park JH; Carillo S; Hermouet S; Girodon F
Blood; 2014 Dec; 124(26):3964-6. PubMed ID: 25305205
[TBL] [Abstract][Full Text] [Related]
19. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.
Chen CC; Gau JP; Chou HJ; You JY; Huang CE; Chen YY; Lung J; Chou YS; Leu YW; Lu CH; Lee KD; Tsai YH
Ann Hematol; 2014 Dec; 93(12):2029-36. PubMed ID: 25015052
[TBL] [Abstract][Full Text] [Related]
20. JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms.
Giraldo-Rincón AI; Naranjo Molina S; Gomez-Lopera N; Aguirre Acevedo D; Ucroz Benavidez A; Gálvez Cárdenas K; Cuellar Ambrosí F; Torres JD; Ospina S; Palacio K; Gaviria Jaramillo L; Muñeton CM; Vasquez Palacio G
Colomb Med (Cali); 2023; 54(3):e2035353. PubMed ID: 38111518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
